Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells
- 1 October 2018
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 123, 56-69
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicinNature Communications, 2013
- Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistanceDrug Resistance Updates, 2012
- Drug-induced Senescence Generates Chemoresistant Stemlike Cells with Low Reactive Oxygen SpeciesJournal of Biological Chemistry, 2011
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerBritish Journal of Cancer, 2011
- Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cellsBritish Journal of Cancer, 2009
- Mismatch Repair Protein Deficiency Compromises Cisplatin-induced Apoptotic SignalingJournal of Biological Chemistry, 2009
- Small molecule induction of MSH2-dependent cell death suggests a vital role of mismatch repair proteins in cell deathDNA Repair, 2008
- Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonistProceedings of the National Academy of Sciences, 2008
- Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changesBritish Journal of Cancer, 2008
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002